AskGene Announces Submission of IND to FDA for ASKG915
Camarillo, California, November 21st, 2022 - AskGene Pharma Inc. is pleased to announce the submission of an Investigational New Drug (IND) application for ASKG915 to ...
AskGene Presents Latest Results on ASKG315 and ASKG915 at SITC 2022
Camarillo, California, November 15th, 2022 - AskGene presented the pre-clinical results of ASKG315 (IL-15 prodrug) and ASKG915 (PD-1/IL-15 prodrug) at the Society for Immunotherapy of ...
AskGene Announces Appointment of Chief Medical Officer and VP of Preclinical & Clinical Pharmacology
Camarillo, California, August 19, 2022 – AskGene Pharma Inc. (AskGene) today announced the appointment of Barbara Hickingbottom, J.D., M.D. as Chief Medical Officer and Matt ...
AskGene Pharma Announces First Development Milestone in License Agreement with AffaMed for the Development of ASKG712 in Retinal Disease
Camarillo, California, June 20, 2022 – AskGene Pharma Inc., an innovative clinical-stage biotech company, announces that its partner AffaMed has dosed the first patient in ...
ASKB589 Achieved Partial Response in Phase I/II Clinical Trial
News, 2022-04-29 AskGene is pleased to announce that its lead program ASKB589 has recently achieved single agent efficacy in its on-going Phase I/II clinical trial ...
AM712 (ASKG712) IND Filing in USA
AffaMed Therapeutics (“AffaMed”), in collaboration with Askgene, announces that the United States Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application ...
ASKG712 IND Filing in China
(Camarillo, California and Nanjing, Jiangsu Province, China) Askgene announces the acceptance of IND to initiate a clinical trial of ASKG712 to treat nAMD (neovascular age ...
GenScript Partnership
On September 26, 2021, GenScript ProBio and AskGene signed a license agreement for GenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target. GenScript ProBio ...
AskGene Pharma Signs a Patent Licensing Agreement
As a subsidiary of Aosaikang Pharm (SZ002755), Askgene Pharma (AskGene) signed a patent licensing agreement (Cross-License Agreement) with Xilio Therapeutics (Xilio), the news was announced ...
